Kumar R, Cartledge W A, Lincoln T M, Pandey K N
Department of Biochemistry and Molecular Biology, Medical College of Georgia, School of Medicine, Augusta 30912-2100, USA.
Hypertension. 1997 Jan;29(1 Pt 2):414-21. doi: 10.1161/01.hyp.29.1.414.
To understand the molecular mechanisms of cellular signaling of atrial natriuretic peptide (ANP), we have studied its effect on the enzymatic activity of endogenous and overexpressed protein kinase C (PKC) in rat thoracic aortic vascular smooth muscle (RTASM) cells. Angiotensin II (ANG II), endothelin-1 (ET-1), and 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated fourfold to fivefold PKC activity in PKC-alpha cDNA-transfected RTASM cells. However, pretreatment of these cells with ANP significantly inhibited the agonist-stimulated PKC activity in a dose-dependent manner. The inhibitory effect of ANP was more effective if cells were transfected with both PKC-alpha and guanylyl cyclase-A/atrial natriuretic peptide receptor (Npra) cDNAs. The agonist-stimulated PKC activity was also inhibited if RTASM cells were pretreated with cGMP analog 8-bromo-cGMP; however, the treatment of cells with a cAMP analog, dibutyryl-cAMP, did not show any discernible effect. The pretreatment of cells with Npra antagonist A-71915, significantly blocked the production of cGMP as well as the inhibitory effect of ANP on PKC activity. To further examine whether the antagonistic action of ANP and 8-bromo-cGMP on agonist-stimulated PKC activity were mediated through cGMP-dependent protein kinase (PKG), cells were treated with ANP or 8-bromo-cGMP and activators of PKC in the presence of KT-5823, a specific inhibitor of PKG. The treatment of cells with KT-5823 significantly attenuated the inhibitory effects of both ANP and 8-bromo-cGMP on agonist-stimulated PKC activity. The results from these studies provide strong evidence that ANP antagonizes the activation of PKC in RTASM cells, involving guanylyl cyclase-A receptor Npra and second messenger cGMP. Our data further support the notion that ANP acts as a negative mediator of signaling cross-talks between Npra and PKC in a cGMP-dependent manner, probably involving cGMP-dependent protein kinase in this process.
为了解心房利钠肽(ANP)细胞信号传导的分子机制,我们研究了其对大鼠胸主动脉血管平滑肌(RTASM)细胞内源性和过表达蛋白激酶C(PKC)酶活性的影响。血管紧张素II(ANG II)、内皮素-1(ET-1)和12-O-十四酰佛波醇-13-乙酸酯(TPA)可使PKC-α cDNA转染的RTASM细胞中的PKC活性提高4至5倍。然而,用ANP预处理这些细胞可显著抑制激动剂刺激的PKC活性,且呈剂量依赖性。如果细胞同时转染了PKC-α和鸟苷酸环化酶-A/心房利钠肽受体(Npra)cDNA,ANP的抑制作用会更有效。如果用cGMP类似物8-溴-cGMP预处理RTASM细胞,激动剂刺激的PKC活性也会受到抑制;然而,用cAMP类似物二丁酰-cAMP处理细胞则未显示出任何明显效果。用Npra拮抗剂A-71915预处理细胞,可显著阻断cGMP的产生以及ANP对PKC活性的抑制作用。为进一步研究ANP和8-溴-cGMP对激动剂刺激的PKC活性的拮抗作用是否通过cGMP依赖性蛋白激酶(PKG)介导,在存在PKG特异性抑制剂KT-5823的情况下,用ANP或8-溴-cGMP以及PKC激活剂处理细胞。用KT-5823处理细胞可显著减弱ANP和8-溴-cGMP对激动剂刺激的PKC活性的抑制作用。这些研究结果提供了有力证据,表明ANP拮抗RTASM细胞中PKC的激活,涉及鸟苷酸环化酶-A受体Npra和第二信使cGMP。我们的数据进一步支持了这样一种观点,即ANP以cGMP依赖性方式作为Npra和PKC之间信号转导相互作用的负调节因子,在此过程中可能涉及cGMP依赖性蛋白激酶。